|
gptkbp:instanceOf
|
gptkb:monoclonal_antibody
immunotherapy
|
|
gptkbp:administeredBy
|
intravenous infusion
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2014
|
|
gptkbp:ATCCode
|
L01XC17
|
|
gptkbp:brand
|
gptkb:Opdivo
|
|
gptkbp:CASNumber
|
946414-94-4
|
|
gptkbp:clinicalTrialPhase
|
Phase III
|
|
gptkbp:combinationTherapy
|
gptkb:ipilimumab
|
|
gptkbp:contraindication
|
hypersensitivity to nivolumab
|
|
gptkbp:cost
|
high
|
|
gptkbp:developedBy
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:halfLife
|
25 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
nivolumab
|
|
gptkbp:immunogenicity
|
low
|
|
gptkbp:indication
|
adjuvant treatment of melanoma
advanced or metastatic cancers
unresectable cancers
|
|
gptkbp:legalStatus
|
prescription only
patented
|
|
gptkbp:mechanismOfAction
|
PD-1 inhibitor
|
|
gptkbp:molecularWeight
|
146 kDa
|
|
gptkbp:monoclonalAntibodyType
|
gptkb:IgG4
|
|
gptkbp:origin
|
gptkb:human
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:prescriptionRequired
|
available from FDA and EMA
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
diarrhea
fatigue
pruritus
hepatitis
rash
inflammatory bowel disease
endocrinopathies
immune-mediated pneumonitis
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:target
|
programmed death-1 (PD-1) receptor
|
|
gptkbp:UNII
|
QDL4447K2P
|
|
gptkbp:usedFor
|
gptkb:non-small_cell_lung_cancer
gptkb:urothelial_carcinoma
gptkb:squamous_cell_carcinoma_of_the_head_and_neck
gptkb:classical_Hodgkin_lymphoma
melanoma
renal cell carcinoma
colorectal cancer (MSI-H/dMMR)
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:programmed_cell_death_protein_1_(PD-1)
|
|
gptkbp:bfsLayer
|
6
|